Susan M. Domchek

TL;DR: The relative risks of developing breast cancer were highest for men in their 30s and 40s and decreased with increasing age, and both the relative and cumulative risks were higher for BRCA2 mutation carriers than forBRCA1 mutation carriers.

TL;DR: These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genesassociated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.

TL;DR: Nearly one‐half of the women at risk for breast cancer had taken no preventive option, relying solely on screening, and there were large differences in the uptake of the different preventive options by country of residence.

TL;DR: Five SNPs on 19p13 were associated with breast cancer risk and an association with estrogen receptor–positive disease in the opposite direction was identified andotyping these SNPs in 6,800 population-based breast cancer cases and 6,613 controls identified a similar association.

TL;DR: If confirmed, the finding that BPSO improves overall survival and cancer-specific survival in women with BRCA mutations will complement the existing knowledge of cancer-risk reduction associated with B PSO and give information to women who are considering genetic testing.